Cypher Genomics said this week that it is offering trial access to Mantis, its genome interpretation technology through a newly launched program called Mantis 5-for-5. This program allows researchers and laboratory directors to run five analyses per month for five months using the company's analysis infrastructure. Interested researchers can sign up online or at the company's booth at American Society of Human Genetics conference in San Diego.
This week, Omicia announced the commercial availability of Opal Clinical, a software solution that helps diagnostic testing organizations launch next-generation sequencing tests faster and interpret results more accurately and quickly.
Its features include support for targeted gene panels, whole exome or genome tests; a complete clinical interpretation workflow, clinical report generation tools, and more.
This week, Cartagenia launched Bench for Oncology, a new software solution that helps pathology laboratories assess, annotate, and report on cancer variants. The solution includes tools to track actionable findings and helps labs automate their variant assessment and reporting pipelines among other features.
The National Center for Biotechnology Information has released dbSNP human Build 142, based on the GRCh38 and GRCh37.p13 assemblies, via NCBI Entrez and ftp. The build provides 112 million reference SNP clusters, including 51 million new RS created from 1000 Genomes Phase III variants as well as from other large sequencing projects.
The NCBI also said this week that Blast instances can now be started from the Amazon Web Services marketplace.
The AWS Blast instance is packaged as an Amazon machine image (AMI), which allows users to run stand-alone searches with the BLAST+ applications; submit searches through a subset of the NCBI-BLAST URL application programing interface; and perform searches with a simplified web page. The BLAST AMI also includes a FUSE client that can download BLAST databases during the first search.
Era7 has launched Genome7, a new analysis resource for cancer genomics projects. According to the company, the offering provides an easy to use interactive web application and access to data repositories that will make interpretation easier.